PTH and Hypocalcemia: The short half‐lives of both calcitriol and currently available PTH‐based therapies lead to daily sCa fluctuations, and stopping or missing a dose can lead to acute symptomatic and debilitating hypocalcemia.14 In contrast, due to its longer half‐life, daily TransCon PTH may lead to more stable sCa levels as well as a lower risk of severe hypocalcemia if a dose is missed.